What amount sold does VisCardia, Inc. report in Form D filings?

The latest linked filings report $22.1M sold across 7 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was VisCardia, Inc.'s most recent SEC filing?

VisCardia, Inc.'s most recent Form D filing was on 2025-10-28.

How many investors does VisCardia, Inc. have?

The most recent Form D filing lists 2 investor(s).

What type of securities does VisCardia, Inc. offer?

VisCardia, Inc.'s SEC Form D filings indicate equity offerings.

VisCardia, Inc.

CIK: 0001676458·Other Technology·BEAVERTON, OR·Corporation

Reported Sold

$22,095,631

Total Filings

Identified Offerings

Last Filed

Oct 28, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Other Technology industry

SEC EDGAR

Offering filing timeline

Oct 28, 2025Form D/A — Amendment

Reported sold: $10,845,631 · Target: $11,500,000

Rule 506(b)·4 investors

Changed: Reported amount sold, Offering target, Reported investors

Oct 28, 2025Form D — New notice

Reported sold: $9,500,000 · Target: $39,500,000

Rule 506(b)·2 investors

Apr 5, 2022Form D — New notice

Reported sold: $1,500,000 · Target: $2,700,000

Rule 506(b)·1 investor

Apr 14, 2021Form D — New notice

Reported sold: $200,000 · Target: $5,000,000

Rule 506(b)·1 investor

Jul 21, 2020Form D — New notice

Reported sold: $0 · Target: $568,432

Rule 506(b)·6 investors

Feb 5, 2019Form D — New notice

Reported sold: $400,000 · Target: $682,119

Rule 506(b)·1 investor

Nov 13, 2017Form D — New notice

Reported sold: $750,000 · Target: $1,421,207

Rule 506(b)·1 investor

Jun 7, 2016Form D — New notice

Reported sold: $400,000 · Target: $2,282,600

Rule 506(b)·1 investor

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

13%

Latest reported sold across 7 identified offerings

$22,095,631

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Peter Bauer

Related Person

Appears on 8 filings

David Chazanovitz

Related Person

Appears on 7 filings

Dallas Ross

Related Person

Appears on 5 filings

Dal Ross

Related Person

Appears on 1 filing

Dallas Ross

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Oct 28, 2025	Amendment	$11,500,000	$10,845,631	4
Oct 28, 2025	New	$39,500,000	$9,500,000	2
Apr 5, 2022	New	$2,700,000	$1,500,000	1
Apr 14, 2021	New	$5,000,000	$200,000	1
Jul 21, 2020	New	$568,432	$0	6
Feb 5, 2019	New	$682,119	$400,000	1
Nov 13, 2017	New	$1,421,207	$750,000	1
Jun 7, 2016	New	$2,282,600	$400,000	1

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Araceli Biosciences Inc.

Other Technology

Offering target: $4,500,000

Filed Nov 3, 2026